Composition and method for vancomycin oral liquid

Abstract

The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

What is claimed is: 
     
         1 .- 17 . (canceled) 
     
     
         18 . A non-sterile stable liquid formulation formulated for oral administration, consisting of:
 (a) a buffering agent, wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and calcium salts,   (b) water,   (c) a sweetener,   (d) sodium benzoate,   (e) vancomycin hydrochloride,   (f) propylene glycol, and   (g) optionally a flavoring agent and/or dye,   wherein the non-sterile stable liquid formulation is homogenous and stable for at least 1 week at ambient and refrigerated temperature and has a pH of 2.5-4.5.   
     
     
         19 . The liquid formulation of  claim 18 , wherein the sodium benzoate is 0.02-0.08% w/v. 
     
     
         20 . The liquid formulation of  claim 18 , wherein the buffering agent is citric acid 0.12% w/v. 
     
     
         21 . The liquid formulation of  claim 18 , wherein the buffering agent is anhydrous citric acid. 
     
     
         22 . The liquid formulation of  claim 18 , wherein the formulation includes a dye. 
     
     
         23 . A non-sterile stable liquid formulation formulated for oral administration, consisting of:
 (a) a buffering agent, wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and calcium salts,   (b) water,   (c) a sweetener,   (d) a preservative, wherein the preservative is selected from the group consisting of sodium benzoate, parabens, benzoic acid, potassium sorbate, benzyl alcohol, or salts thereof   (e) vancomycin hydrochloride,   (f)) propylene glycol, and   (g) optionally a flavoring agent and/or dye,   wherein the non-sterile stable liquid formulation is homogenous and stable for at least 1 week at ambient and refrigerated temperature and has a pH of 2.5-4.5.   
     
     
         24 . The liquid formulation of  claim 23 , wherein the buffering agent is citric acid 0.12% w/v. 
     
     
         25 . The liquid formulation of  claim 23 , wherein the buffering agent is anhydrous citric acid. 
     
     
         26 . A method of treating  Clostridium difficile  pseudomembranous colitis or Staphylococcal enterocolitis in a subject comprising administering a vancomycin oral liquid composition to the subject in a therapeutically effective amount, wherein the vancomycin oral liquid composition consists of:
 (a) a buffering agent, wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and calcium salts,   (b) water,   (c) a sweetener,   (d) a preservative, wherein the preservative is selected from the group consisting of sodium benzoate, parabens, benzoic acid, potassium sorbate benzyl alcohol, or salts thereof   (e) vancomycin hydrochloride,   (f)) propylene glycol, and   (g) optionally a flavoring agent and/or dye,   wherein the vancomycin oral liquid composition is homogenous and stable for at least 1 week at ambient and refrigerated temperature and has a pH of 2.5-4.5.   
     
     
         27 . The method of  claim 26 , wherein the buffering agent is citric acid 0.12% w/v. 
     
     
         28 . The method of  claim 26 , wherein the buffering agent is anhydrous citric acid. 
     
     
         29 . The method of  claim 26 , wherein the sweetener is 0.1-0.3% w/v. 
     
     
         30 . The method of  claim 26 , wherein the formulation includes a dye. 
     
     
         31 . The method of  claim 26 , wherein the preservative is sodium benzoate.